Forgot your password?
Skip Navigation Links
Univar's (UNVR) Q1 Earnings Trail Estimates, Revenues Top
May 09, 2017 ( via COMTEX) -- Copyright (C) 2017, Zacks Investment Research.

Univar UNVR logged a profit (on a reported basis) of $22.6 million or 16 cents per share in first-quarter 2017, up around 61% from a profit of $14 million or 10 cents per share a year ago.Barring one-time items, earnings came in at 19 cents per share in the quarter, missing the Zacks Consensus Estimate of 22 cents.The chemical maker's revenues were essentially flat year over year at $1,998.8 million in the reported quarter as lower volumes were offset by increased selling prices. Sales beat the Zacks Consensus Estimate of $1,933 million.Gross profit rose around 2% year over year to $439.4 million in the quarter on the back of the company's margin management actions and favorable product and market mix.Univar Inc. Price, Consensus and EPS Surprise Univar Inc. Price, Consensus and EPS Surprise | Univar Inc. QuoteSegment ReviewRevenues from the USA division fell around 3% year over year to $1.2 billion in the reported quarter, affected by reduced volumes that more than offset improved pricing. Gross profit was flat year over year at $262.9 million.Revenues from the Canada segment went up around 13% to $307.3 million, driven by increased sales in the Western Canada oil and gas market. Gross profit rose roughly 10% to $55.8 million on higher sales.The EMEA segment raked in sales of $439.7 million, up 0.5%, helped by higher selling prices. Gross profit rose around 6% to $101.8 million, supported by favorable market mix.Sales from the Rest of World unit fell 0.5% to $100.9 million as softer demand in Mexico and sluggish economic conditions in Brazil more the offset higher pricing. Gross profit fell around 8% to $18.9 million, hurt by weak economic conditions in Mexico.Balance SheetUnivar ended the quarter with cash and cash equivalents of $300.6 million, up around 35% year over year. Long-term debt was $2,905.7 million, down around 6% year over year.OutlookUnivar said that it will remain focused on executing its growth and productivity plans. The company sees mid-single digit growth in adjusted EBITDA in the first half of 2017 and expects to deliver mid-to-high single digit growth in adjusted EBITDA for the full year.For second-quarter 2017, Univar expects adjusted EBITDA growth of mid-single digits from previous year's second quarter figure of $148.2 million.Price PerformanceUnivar has significantly outperformed the Zacks categorized Chemicals-Diversified industry over a year. The company's shares have gained 77% over this period compared with the industry's gain of 19.3% over the same period. Zacks Rank & Key PicksUnivar is a Zacks Rank #2 (Buy) stock.Other well-placed companies in the chemical space include The Chemours Company CC, Huntsman Corporation HUN and Kronos Worldwide, Inc. KRO, all holding a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.Chemours has an expected long-term growth of 15.5%.Huntsman has an expected long-term growth of 7.8%.Kronos has an expected long-term growth of 5%.Zacks' Best Private Investment Ideas While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades... from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>

Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Investment Research.See all today's Analyst Blog entries.

News Provided by COMTEX
Privacy Statement | Copyright © 2017 The Plastics Exchange. LLC. | Patent Protected | All Rights Reserved.